BioCentury | Dec 21, 2018
Financial News

Erasca launches to target cancer drivers

...Bonti Inc., Eclipse Therapeutics Inc. and Halozyme Therapeutics Inc. (NASDAQ:HALO). This year, Allergan plc (NYSE:AGN) acquired Bonti...
BioCentury | Dec 18, 2018
Financial News

Erasca launches to target cancer drivers

...Bonti Inc., Eclipse Therapeutics Inc. and Halozyme Therapeutics Inc. (NASDAQ:HALO). This year, Allergan plc (NYSE:AGN) acquired Bonti...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...$687 $769 Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Syntimmune Inc. 9/26/18 $400 $800 $1,200 Allergan plc (NYSE:AGN) Bonti Inc....
BioCentury | Sep 21, 2018
Company News

Allergan to acquire botulinum neurotoxin play Bonti

...million up front. Bonti shareholders are also eligible for undisclosed commercial milestone payments. Allergan and Bonti...
...diseases, medical aesthetics and eye care. Through the acquisition, Allergan will obtain global rights to Bonti's...
...IIa" ). Bonti Inc., Newport Beach, Calif. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Dermatology, Neurology Sandi Wong EB-001A EB-001T Allergan Inc. Bonti Inc. BoNT/E...
BioCentury | Aug 10, 2018
Clinical News

Bonti's EB-001A improves scar appearance following Mohs surgery in Phase IIa

...immediately following Mohs surgery. EB-001A is a botulinum neurotoxin serotype E (BoNT/E) for aesthetic application. Bonti Inc....
...following Mohs surgery Endpoint: Scar appearance; itching and pain Status: Phase IIa data Milestone: NA Sandi Wong EB-001A Bonti Inc....
BioCentury | Feb 2, 2018
Financial News

Bonti raises $15.5M in series C

...Botulinum neurotoxin play Bonti Inc. (Newport Beach, Calif.) raised $15.5 million on Jan. 23 in a series...
...pain. The candidate is a botulinum neurotoxin serotype E (BoNT/E). Bonti Inc., Newport Beach, Calif. Elizabeth S. Eaton Bonti Inc....
BioCentury | Jan 24, 2018
Company News

Management tracks: Gritstone, Disarm, Symic

...Scigalla is CMO of oncolytic virus company Genelux Corp. (San Diego, Calif.). Botulinum neurotoxin play Bonti Inc....
BioCentury | Apr 20, 2017
Financial News

Bonti completes venture financing

...Botulinum neurotoxin play Bonti Inc. (Newport Beach, Calif.) raised $11.7 million in a series B round on...
...JMCR Partners and HighLight Capital participated. Existing investors also participated. Bonti Inc. , Newport Beach, Calif. Alicia Parker Bonti Inc....
Items per page:
1 - 8 of 8
BioCentury | Dec 21, 2018
Financial News

Erasca launches to target cancer drivers

...Bonti Inc., Eclipse Therapeutics Inc. and Halozyme Therapeutics Inc. (NASDAQ:HALO). This year, Allergan plc (NYSE:AGN) acquired Bonti...
BioCentury | Dec 18, 2018
Financial News

Erasca launches to target cancer drivers

...Bonti Inc., Eclipse Therapeutics Inc. and Halozyme Therapeutics Inc. (NASDAQ:HALO). This year, Allergan plc (NYSE:AGN) acquired Bonti...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...$687 $769 Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Syntimmune Inc. 9/26/18 $400 $800 $1,200 Allergan plc (NYSE:AGN) Bonti Inc....
BioCentury | Sep 21, 2018
Company News

Allergan to acquire botulinum neurotoxin play Bonti

...million up front. Bonti shareholders are also eligible for undisclosed commercial milestone payments. Allergan and Bonti...
...diseases, medical aesthetics and eye care. Through the acquisition, Allergan will obtain global rights to Bonti's...
...IIa" ). Bonti Inc., Newport Beach, Calif. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Dermatology, Neurology Sandi Wong EB-001A EB-001T Allergan Inc. Bonti Inc. BoNT/E...
BioCentury | Aug 10, 2018
Clinical News

Bonti's EB-001A improves scar appearance following Mohs surgery in Phase IIa

...immediately following Mohs surgery. EB-001A is a botulinum neurotoxin serotype E (BoNT/E) for aesthetic application. Bonti Inc....
...following Mohs surgery Endpoint: Scar appearance; itching and pain Status: Phase IIa data Milestone: NA Sandi Wong EB-001A Bonti Inc....
BioCentury | Feb 2, 2018
Financial News

Bonti raises $15.5M in series C

...Botulinum neurotoxin play Bonti Inc. (Newport Beach, Calif.) raised $15.5 million on Jan. 23 in a series...
...pain. The candidate is a botulinum neurotoxin serotype E (BoNT/E). Bonti Inc., Newport Beach, Calif. Elizabeth S. Eaton Bonti Inc....
BioCentury | Jan 24, 2018
Company News

Management tracks: Gritstone, Disarm, Symic

...Scigalla is CMO of oncolytic virus company Genelux Corp. (San Diego, Calif.). Botulinum neurotoxin play Bonti Inc....
BioCentury | Apr 20, 2017
Financial News

Bonti completes venture financing

...Botulinum neurotoxin play Bonti Inc. (Newport Beach, Calif.) raised $11.7 million in a series B round on...
...JMCR Partners and HighLight Capital participated. Existing investors also participated. Bonti Inc. , Newport Beach, Calif. Alicia Parker Bonti Inc....
Items per page:
1 - 8 of 8